Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes
CompletedPhase 3Results postedLast updated 19 February 2018
What this trial tests
Phase 3 trial testing insulin degludec/liraglutide in Diabetes in 1,663 participants. Completed in 22 November 2012.
18 and older, any sex, with Diabetes or Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Mean Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 26.Primary· Week 0, week 26
Values of mean change in HbA1c.
Group
Value
95% CI
IDeg
-1.44
± 1.03
IDegLira
-1.91
± 1.07
Liraglutide
-1.28
± 1.13
Mean Change From Baseline in Body Weight at Week 26Secondary· Week 0, Week 26
Values of mean change in body weight.
Group
Value
95% CI
IDeg
1.6
± 4.0
IDegLira
-0.5
± 3.5
Liraglutide
-3.0
± 3.5
Number of Hypoglycaemic EpisodesSecondary· Weeks 0-26
Reported hypoglycemaic episodes are number of hypoglycemic events per 100 patient years of exposure.
Group
Value
95% CI
IDeg
256.7
IDegLira
180.2
Liraglutide
22.0
Change From Baseline in Incremental Area Under the Curve 0-4h (iAUC0-4h) Derived From the Glucose Concentration Profile During Meal TestSecondary· Week 0, Week 26
Values of mean change in normalised iAUC0-4h values based on LOCF data derived from the glucose concentration profiles during a meal test. The meal test was performed at selected sites at baseline and after 26 weeks of treatment in the main trial period. The incremental AUC was calculated using the trapezoidal method and the resulting area was divided length of the observation period to yield the (normalised) prandial increment in mmol/L using the available valid glucose observations and the associated actual elapsed time point.
Group
Value
95% CI
IDeg
-0.17
± 1.98
IDegLira
-0.87
± 1.65
Liraglutide
-0.78
± 1.62
Mean Actual Daily Insulin DoseSecondary· Week 26
Mean of the actual doses recorded at visit 28 (Week 26).
Group
Value
95% CI
IDeg
53
± 28
IDegLira
38
± 13
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse events (AEs) were collected from first day of exposure to randomised treatment of 52 weeks (26 week main period + 26 week extension period) + 7 days follow-up after the last day on randomised treatment..
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This trial is conducted globally. The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin degludec (IDeg) and liraglutide (Lira) in subjects with type 2 diabetes. Subjects are to continue their pre-trial treatment with metformin or metformin + pioglitazone throughout the entire trial.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06449703 — A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide in Healthy Chinese Subjects
· Phase 1
· recruiting
NCT03292185 — A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec a
· Phase 1
· completed
NCT03070704 — Non-interventional, Post Marketing Surveillance Study of Xultophy™ (Insulin Degludec/Liraglutide) to Evaluate Long Term
· withdrawn
NCT02773368 — A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargi
· Phase 3
· completed
NCT02754817 — A Study of the Effectiveness of Xultophy® (Insulin Degludec/Liraglutide) in an Adult Real-world Population With Type 2 D
· completed
Other recruiting trials for Diabetes
Currently open trials in the same condition.
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass
· recruiting
NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells
· NA
· recruiting
NCT07441655 — Families Implementing Good Health Traditions for Life
· NA
· recruiting
NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity
· NA
· recruiting
NCT07357740 — A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes
· Phase 2
· not yet recruiting
NCT07282613 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adoles
· Phase 3
· not yet recruiting
NCT07357766 — A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight
· Phase 3
· not yet recruiting
NCT07564414 — A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obe
· Phase 3
· not yet recruiting
NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc
· Phase 3
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novo Nordisk A/S
Last refreshed: 19 February 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01336023.